OCTA在雷珠单克隆抗体治疗视网膜分支静脉阻塞合并黄斑水肿视力预测中的应用分析  

Application of OCTA in the prediction of visual acuity of treatment of retinal branch vein occlusion with macular edema by ranibizumab

作　　者：徐冲[1] 冯超[1] 吴建华[1] Xu Chong;Feng Chao;Wu Jianhua(Aier Eye Hospital of Wuhan,Wuhan,Hubei 430064,China)

机构地区：[1]武汉爱尔眼科医院,430064

出　　处：《临床眼科杂志》2018年第5期390-393,共4页Journal of Clinical Ophthalmology

摘　　要：目的分析31例(31只眼)经玻璃体腔注射雷珠单克隆抗体治疗视网膜分支静脉阻塞(BRVO)并发黄斑水肿患者的临床资料,评估相干光断层扫描血管成像(OCTA)测量黄斑区无血管区面积在预测患者视力改善中的作用。方法采用回顾性分析31例经玻璃体腔注射雷珠单克隆抗体治疗BRVO并发黄斑水肿的患者,比较治疗前后视力的改善和黄斑水肿消退的情况,同时对所有患者的年龄、病程、黄斑区无血管区面积、治疗前视力、治疗前黄斑中心凹厚度、治疗后降低的黄斑中心凹厚度与提高的视力进行多因素回归分析。结果所有患者经过治疗后,最佳矫正视力(BCVA)和黄斑中心凹厚度与治疗前相比有统计学差异(t=-4. 8493,P <0. 001; t=16. 7172,P <0. 001),患者的年龄、黄斑区无血管面积和治疗前BCVA与最后提高的视力之间呈负相关(t=-2. 620,P=0. 014; t=-3. 878,P <0. 001; t=-2=4. 284,P <0. 001),病程、治疗前黄斑中心凹厚度、治疗后降低的黄斑中心凹厚度与最后提高的视力之间无明显相关性(t=-0. 903,P=0. 375; t=-0. 774,P=0. 446; t=-1. 007,P=0. 323)。结论雷珠单克隆抗体治疗BRVO并发黄斑水肿,黄斑水肿明显消退,视力改善。其中,年龄、黄斑区无血管面积、治疗前BCVA有可能是影响视力改善程度的相关因子。Objective To analyze the clinical data of 31 cases of retinal vein occlusion complicated with macular edema treated by intravitreal injection of ranibizumab, and to evaluate the improvement of the visual acuity of the patients measured by Optical coherence tomography angiography （OCTA）. Methods Retrospective analysis of 31 patients with branch retinal vein occlusion complicated with macular edema treated by intravitreal injection of ranibizumab, comparing the improvement of visual acuity before and after treatment and the decline of macular edema. Meanwhile, age, course of disease, area of macular area, visual acuity before treatment, macular fovea thickness before treatment, macular fovea thickness after treatment and visual acuity improved were analyzed by using multiple factors regression. Results After treatment, the best corrected visual acuity and macular fovea thickness of all patients were significantly different from those before treatment （ t =-4.8493, P 〈0.001; t =16.7172, P 〈0.001）. There was a negative correlation between the age of patients, the macular area and the best corrected visual acuity before treatment and the final improvement of vision （ t =-2.620, P =0.014, t =-3.878, P 〈0.001; t =-2=4.284, P 〈0.001）. There was no significant correlation between the duration of disease, the thickness of macular fovea before treatment, the thickness of macular fovea after treatment, and the final improvement of visual acuity （ t =-0.903, P =0.375; t =-0.774, P =0.446; t =-1.007, P =0.323）. Conclusions Treatment with retinal branch vein occlusion and macular edema with ranibizumab, macular edema significantly resolved, and visual acuity improved. Age, foveal avascular zone area and best corrected visual acuity before treatment may be related factors affecting the improvement of visual acuity.

关 键 词：视网膜分支静脉阻塞 黄斑水肿 雷珠单克隆抗体 

分 类 号：R774[医药卫生—眼科]